BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28424149)

  • 1. Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study.
    Roumie CL; Min JY; D'Agostino McGowan L; Presley C; Grijalva CG; Hackstadt AJ; Hung AM; Greevy RA; Elasy T; Griffin MR
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28424149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.
    Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Murff HJ; Elasy TA; Griffin MR
    JAMA; 2014 Jun; 311(22):2288-96. PubMed ID: 24915260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
    Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
    Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline.
    Hung AM; Roumie CL; Greevy RA; Grijalva CG; Liu X; Murff HJ; Ikizler TA; Griffin MR
    Clin J Am Soc Nephrol; 2016 Dec; 11(12):2177-2185. PubMed ID: 27827311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas.
    Chu PY; Hackstadt AJ; Chipman J; Griffin MR; Hung AM; Greevy RA; Grijalva CG; Elasy T; Roumie CL
    Diabetes Care; 2020 Jul; 43(7):1462-1470. PubMed ID: 32327421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study.
    Huizinga MM; Roumie CL; Greevy RA; Liu X; Murff HJ; Hung AM; Grijalva CG; Griffin MR
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1108-12. PubMed ID: 20878643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
    Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
    J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea.
    Roumie CL; Min JY; Greevy RA; Grijalva CG; Hung AM; Liu X; Elasy T; Griffin MR
    CMAJ; 2016 Apr; 188(6):E104-E112. PubMed ID: 26811361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.
    McCormick N; Yokose C; Lu N; Wexler DJ; Aviña-Zubieta JA; De Vera MA; McCoy RG; Choi HK
    JAMA Intern Med; 2024 Jun; 184(6):650-660. PubMed ID: 38619822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation of sulfonylureas versus metformin is associated with higher blood pressure at one year.
    Roumie CL; Liu X; Choma NN; Greevy RA; Hung AM; Grijalva CG; Griffin MR
    Pharmacoepidemiol Drug Saf; 2012 May; 21(5):515-23. PubMed ID: 22431419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
    JAMA Intern Med; 2021 Aug; 181(8):1043-1053. PubMed ID: 34180939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
    Filion KB; Douros A; Azoulay L; Yin H; Yu OH; Suissa S
    Br J Clin Pharmacol; 2019 Oct; 85(10):2378-2389. PubMed ID: 31276600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
    Anyanwagu U; Mamza J; Mehta R; Donnelly R; Idris I
    Heart; 2016 Oct; 102(19):1581-7. PubMed ID: 27217068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of metformin versus sulfonylureas on kidney function decline or death among patients with reduced kidney function: a retrospective cohort study.
    Hung AM; Hackstadt AJ; Griffin MR; Grijalva CG; Greevy RA; Roumie CL
    CMAJ Open; 2023; 11(1):E77-E89. PubMed ID: 36720491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospitalization for Heart Failure Among Patients With Diabetes Mellitus and Reduced Kidney Function Treated With Metformin Versus Sulfonylureas: A Retrospective Cohort Study.
    Richardson TL; Hackstadt AJ; Hung AM; Greevy RA; Grijalva CG; Griffin MR; Elasy TA; Roumie CL
    J Am Heart Assoc; 2021 Apr; 10(8):e019211. PubMed ID: 33821674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy.
    Salas J; Morley JE; Scherrer JF; Floyd JS; Farr SA; Zubatsky M; Barthold D; Dublin S
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):623-634. PubMed ID: 32363681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.
    He S; Qian X; Chen Y; Shen X; Zhang B; Chen X; Xu X; Li G
    J Diabetes Res; 2021; 2021():5534387. PubMed ID: 34222493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.